trending Market Intelligence /marketintelligence/en/news-insights/trending/rl9ffgxvzwdbhf_elmmyeq2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it failed to comply with Nasdaq's $1 minimum bid price per common share.

The company has 180 calendar days, or until Feb. 25, 2019, to regain compliance.

The current notice has no immediate effect on the company's listing.

New Jersey-based ContraVir Pharmaceuticals develops antiviral drugs with a focus on hepatitis B.